Related Experiment Videos

In-vitro activity of azithromycin and CP-63,956 against Treponema pallidum

L V Stamm1, E A Parrish

  • 1Department of Parasitology, School of Public Health, University of North Carolina, Chapel Hill 27599-7400.

Insights

Azithromycin and CP-63,956 effectively inhibit protein synthesis in Treponema pallidum. However, an erythromycin-resistant strain showed only partial inhibition, suggesting potential resistance mechanisms to macrolide antibiotics.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Treponema pallidum is a pathogenic bacterium responsible for syphilis.
  • Macrolide antibiotics, such as erythromycin, are used to treat syphilis.
  • Emergence of antibiotic resistance in T. pallidum poses a significant challenge to treatment efficacy.

Purpose of the Study:

  • To investigate the efficacy of azithromycin and its epimer CP-63,956 in inhibiting protein synthesis in pathogenic Treponema pallidum strains.
  • To compare the activity of these macrolides against both a standard strain and an erythromycin-resistant clinical isolate.

Main Methods:

  • In vitro protein synthesis inhibition assay using radiolabelling.
  • Treponemes were freshly extracted from infected rabbit testes.
  • Tested azithromycin, CP-63,956, and erythromycin against T. pallidum Nichols strain and T. pallidum Street strain 14.

Main Results:

  • Azithromycin and CP-63,956 demonstrated comparable inhibition of protein synthesis to erythromycin in the T. pallidum Nichols strain.
  • The erythromycin-resistant T. pallidum Street strain 14 exhibited only partial inhibition, even at high antibiotic concentrations.

Conclusions:

  • Azithromycin and CP-63,956 show potent in vitro activity against susceptible T. pallidum strains.
  • The findings highlight the potential for erythromycin resistance in T. pallidum and suggest that azithromycin may also be affected in resistant strains.

Related Concept Videos